Jul
2001
Recombinant activated factor VII (RFVIIa): Characterization, manufacturing, and clinical development.
Semin Thromb Hemostasis 2001;27(4):373-383.
NATA Rating :
Review by : M. Aldouri
NATA Review
A good overall review on the
characterization, mechanism of action, and preclinical and current clinical
evidence for the efficacy and safety of rFVIIa.
characterization, mechanism of action, and preclinical and current clinical
evidence for the efficacy and safety of rFVIIa.
– M. Aldouri.
